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Objective: The c.3909C>G (N1303K) is the most frequent mutation after the
c.1521_1523delCTT (F508del) in Lebanon. A CFTR gene screening was performed
on 10 Lebanese and 5 French CF patients carrying c.3909C>G. Parental studies
revealed that all individuals have an association of c.3909C>G (exon 24) with
c.869+11C>T (intron 7) in cis, inducing a new complex allele (CA). Since both
mutations are located in two distant regions, we studied their combined impact by
two plasmid constructions.
Method: Firstly, we studied the impact of c.3909C>G on alternative splicing (AS),
localization and maturation of the CFTR protein. Secondly, to study the impact of
c.869+11C>T on AS, an ex-vivo study will be conducted using a plasmid containing
the exon 7 and its ﬂanking introns. After transfection of different type of eukaryotic
cells, RNA extraction and RT-PCR, cDNA will be sequenced to verify the possible
AS.
Results: We showed that c.3909C>G affects the localization and the process. The
in-silico study is in favor for a possible role of c.869+11C>T in AS. In fact, the
used algorithm human splicing Finder showed that c.869+11C>T might affect the
AS since it is located near the donor site.
Conclusion: The class II mutation, c.3909C>G, induces mild phenotype with
few CFTR on membrane. We suggest that the CA c.[869+11C>T;3909C>G], will
act like a class I mutation, explaining the severe phenotype in some c.3909C>G
patients. So, the classiﬁcation of a mutation is not sufﬁcient in a clinical approach,
as the possible presence of a CA may alter its the speciﬁc effect. Therefore, an
individualized approach is required to perform proper diagnostic and treatment
when available.
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Objectives: L997F is causative of Cystic Fibrosis (CF) classic form when it is in
cis with R117L mutation. In order to assess clinical characteristics and genotype
of patients carrying L997F we retrospectively evaluated a cohort of CF patients in
follow-up at two CF care Centers.
Methods: Complex alleles such as L997F- R117L were searched by CFTR
sequencing analysis. For all patients included in the study (mean age: 26 years,
range 4 months − 49 years) data were collected as age and symptoms at diagnosis,
chloride level at sweat test, sputum, radiological features, pancreatic status and
forced expiratory volume in one second (FEV1). L997F mutation has been detected
in 19/505 (3.7%) patients; 18/19 are compound heterozygous for other CFTR
causing mutations. No detection of R117L mutation in cis or other complex alleles
has been found. Mean age at diagnosis is 16.8 years (range 4 months-37 years).
10/19 were diagnosed by neonatal screening, 3/19 by respiratory symptoms, 2/19 by
recurrent pancreatitis and 4/19 by familiarity. All patients are pancreatic sufﬁcient.
At diagnosis sweat test was negative/borderline in 18/19 cases. Patients with a
longer follow up showed a slower progression of lung disease and no chronic
infections by Pseudomonas aeruginosa. The only homozygous patient for L997F
(age 18.5 years) shows chronic bronchitis, nasal polyposis and a borderline sweat
test (Cl− 58mEq/L)
Conclusion: L997F mutation could be responsible of a variable phenotype of
CFTR-related disorders despite the absence of R117L mutation in cis.
A regular follow up could be mandatory to deﬁne the role of L997F and the
inclusion of this mutation of unclear signiﬁcance in screening panels.
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The in-depth analysis of the CFTR gene, that consists in exploring all the coding
exons their ﬂanking regions and targeted intronic sequences, leads to the frequent
identiﬁcation of private point mutations in patients. It is difﬁcult to establish a priori
the effect of rare intronic, synonymous or missense variants on the function of the
encoded protein and subsequently their involvement in the disease. Consequently,
we previously designed a classiﬁcation method for the evaluation of their impact
on splicing which provides strong arguments to select variants that require further
analysis of nasal epithelial cell transcripts in the patients. For this purpose, we have
now developed a multiplex ﬂuorescent PCR for the one-step analysis of alternative
and/or aberrant splicing of CFTR mRNA. We designed four different mix, using
FAM-labelled forward primers, that contain the whole CFTR transcript in 26
overlapping fragments. We also included an internal control amplifying a sequence
of the ALAS1 transcript. PCR products were then analysed by relative quantiﬁcation
after capillary electrophoresis migration on the 3130XL Genetic Analyzer. In a
ﬁrst step we have set the optimal conditions for a balanced ampliﬁcation of each
amplicon using mRNA from T84 cells, known to express CFTR. The validation
of this method is underway using mRNA from nasal epithelial cells of healthy
individuals and patients carrying an identiﬁed splicing mutation. By quantifying
aberrant splicing effect, this method should play its full role in the characterization
and classiﬁcation of rare genomic variants of unknown clinical signiﬁcance.
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Due to the large extension of CFTR gene (~190kb) and the large number of
gene variants reported (>1900) there’s a need to establish quick methods for
mutation analysis. Usually this is achieved by limiting analysis to the most common
mutations. However, this often leads to difﬁculties in CF genotype identiﬁcation,
especially in populations with high prevalence on non-p.F508del mutations.
We have designed a mRNA-based protocol using just 9 RT-PCR reactions, hereby
the complete CFTR coding region is analysed. Moreover, one of the reactions (exons
11−13) is based on ARMS for p.F508del mutation, which allows easy detection of
this mutation.
We have applied this protocol to genotype 12 CF patients with absence or just
residual CFTR-mediated Cl− secretion in rectal biopsies and only 1 CFTR mutation
identiﬁed by routine methods.
Using this strategy we detected mRNA alterations in 75% of the patients and
identiﬁed the 2nd mutation, conﬁrmed by genomic DNA sequencing. For 2 siblings
we detected a cryptic exon between exons 10−11 resulting from a mutation
far deep into IVS 10 (c.1584+18672A>G), unlikely to be detected by CFTR
exon sequencing. The other mutations detected were: p.G576A, c.1717−1G>A,
c.1812−1G>A, c.3272−26A>G, c.3120+1G>A (2P) (legacy nomenclature).
We conclude that this is a rapid, robust and inexpensive method to detect rare
mutations that can be easily used after a ﬁrst screen. Furthermore it already
demonstrates the functional consequences of mutations in case they occur at the
RNA level.
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